- Asked by: Dawn Black, MSP for Angus North and Mearns, Scottish National Party
-
Date lodged: Tuesday, 06 October 2026
-
Current Status:
Answer expected on 3 November 2026
To ask the Scottish Government when it will bring into force section 60 of the Housing (Scotland) Act 2025, which transfers jurisdiction for Mobile Homes Act 1983 disputes to the First-tier Tribunal (Housing and Property Chamber).
Answer
Answer expected on 3 November 2026
- Asked by: Dawn Black, MSP for Angus North and Mearns, Scottish National Party
-
Date lodged: Wednesday, 30 September 2026
-
Current Status:
Taken in the Chamber on 8 October 2026
To ask the Scottish Government when it expects to commence the remaining provisions of the Children (Scotland) Act 2020 relating to child contact cases, including those that can address delays affecting grandparents seeking to maintain contact with their grandchildren.
Answer
Taken in the Chamber on 8 October 2026
- Asked by: Dawn Black, MSP for Angus North and Mearns, Scottish National Party
-
Date lodged: Wednesday, 23 September 2026
-
Current Status:
Taken in the Chamber on 30 September 2026
To ask the Scottish Government what action it is taking to reduce barriers and to support housing providers to accelerate the delivery of affordable homes across Scotland.
Answer
Taken in the Chamber on 30 September 2026
- Asked by: Dawn Black, MSP for Angus North and Mearns, Scottish National Party
-
Date lodged: Wednesday, 02 September 2026
-
Current Status:
Taken in the Chamber on 9 September 2026
To ask the Scottish Government how it is engaging with the National Energy System Operator to ensure that the development of Regional Energy Strategic Plans support democratic decision-making and meaningful local engagement in energy planning.
Answer
Taken in the Chamber on 9 September 2026
- Asked by: Dawn Black, MSP for Angus North and Mearns, Scottish National Party
-
Date lodged: Wednesday, 15 July 2026
-
Current Status:
Answered by Maree Todd on 10 August 2026
To ask the Scottish Government what plans it has to carry out a rapid review of the available evidence on the risks associated with the long-term use of the contraceptive injection, Depo-Provera.
Answer
The Medicines and Healthcare products Regulatory Agency (MHRA) has responsibility for the quality, safety, and efficacy of medicines through its licensing and pharmacovigilance functions, which are reserved matters.
The MHRA continues to closely monitor the safety of Depo-Provera®, as it does with all licensed medicines, and is examining recent data and seeking advice from experts on the need for any further action. Given this ongoing work, I have no plans to commission a separate evidence review.
- Asked by: Dawn Black, MSP for Angus North and Mearns, Scottish National Party
-
Date lodged: Wednesday, 15 July 2026
-
Current Status:
Answered by Maree Todd on 10 August 2026
To ask the Scottish Government what steps it is taking to ensure that healthcare professionals across all NHS boards are aware of the potential risks associated with the long-term use of the contraceptive injection, Depo-Provera, and that users receive clear, consistent and appropriate advice.
Answer
On 29 June, I met with women affected by Depo-Provera® to listen directly to their experiences and concerns. I was grateful for the opportunity to hear their accounts and to better understand the challenges they face.
At that meeting, I agreed that the Chief Pharmaceutical Officer would issue a letter directly to healthcare professionals in Scotland to ensure that they (1) are aware of the risks associated with the long-term use of Depo-Provera®, (2) describe these risks clearly to women, (3) review prescribing of Depo-Provera® every two years, in line with the Faculty of Sexual & Reproductive Healthcare guidance, and (4) are aware of any actions they should take in the event that a meningioma is suspected.
The letter will also emphasise the importance of Yellow Card reporting of Adverse Drug Reactions (ADRs). The MHRA’s UK-wide Yellow Card reporting system collects data on ADRs and the MHRA monitors these as part of its pharmacovigilance responsibility. Healthcare professionals and/or any member of the public who suffers a suspected ADR should complete and send a Yellow Card report which is used to identify and monitor medicine safety.
- Asked by: Dawn Black, MSP for Angus North and Mearns, Scottish National Party
-
Date lodged: Wednesday, 03 June 2026
-
Current Status:
Taken in the Chamber on 9 June 2026
To ask the Scottish Government whether it will provide an update on progress of the business plan for the A90/A937 Laurencekirk Junction Improvement Scheme, including when it expects the scheme to move from the development pipeline to the delivery pipeline.
Answer
Taken in the Chamber on 9 June 2026